Home › Research › Caregiving
A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P et al.. Nature, 2000-12-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Vaccinations with amyloid-beta peptide (A beta) can dramatically reduce amyloid deposition in a transgenic mouse model of Alzheimer's disease. To determine if the vaccinations had deleterious or beneficial functional consequences, we tested eight months of A beta vaccination in a different transgenic model for Alzheimer's disease in which mice develop learning deficits as amyloid accumulates. Here we show that vaccination with A beta protects transgenic mice from the learning and age-related memory deficits that normally occur in this mouse model for Alzheimer's disease. During testing for potential deleterious effects of the vaccine, all mice performed superbly on the radial-arm water-maze test of working memory. Later, at an age when untreated transgenic mice show memory deficits, the A beta-vaccinated transgenic mice showed cognitive performance superior to that of the control transgenic mice and, ultimately, performed as well as nontransgenic mice. The A beta-vaccinated mice also had a partial reduction in amyloid burden at the end of the study. This therapeutic approach may thus prevent and, possibly, treat Alzheimer's dementia.
What this study adds
Evidence grade: Low
In a mouse model of Alzheimer's, vaccination with amyloid-beta protected the mice from learning and memory deficits and partially reduced amyloid buildup. Its stated limit: This is a mouse model study; protecting genetically engineered mice from memory deficits does not guarantee the same approach will be safe or effective in human Alzheimer's disease, which the subsequent two decades of human trials have shown is a much harder problem.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C., Hardy, J., et al. (2000). A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. https://doi.org/10.1038/35050116
Vancouver
Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 2000. doi:10.1038/35050116. PMID: 11140686.
BibTeX
@article{morgan2000-11140686,
author = {Morgan, D. and Diamond, D. M. and Gottschall, P. E. and Ugen, K. E. and Dickey, C. and Hardy, J. and Duff, K. and Jantzen, P. and others},
title = {{A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease}},
journal = {Nature},
year = {2000},
doi = {10.1038/35050116},
pmid = {11140686},
url = {https://doi.org/10.1038/35050116}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Here we show that vaccination with A beta protects transgenic mice from the learning and age-related memory deficits that normally occur in this mouse model for Alzheimer's disease.
- During testing for potential deleterious effects of the vaccine, all mice performed superbly on the radial-arm water-maze test of working memory.
- Later, at an age when untreated transgenic mice show memory deficits, the A beta-vaccinated transgenic mice showed cognitive performance superior to that of the control transgenic mice and, ultimately, performed as well as nontransgenic mice.
- The A beta-vaccinated mice also had a partial reduction in amyloid burden at the end of the study.
- This therapeutic approach may thus prevent and, possibly, treat Alzheimer's dementia.
Why it matters
In a mouse model of Alzheimer's, vaccination with amyloid-beta protected the mice from learning and memory deficits and partially reduced amyloid buildup. This is an early animal study, so it does not yet show whether such a vaccine would prevent or treat Alzheimer's in people.
New to this subject? Start with our plain-English guide: Caregiving →
Study details
- Evidence strengthLow
Limitations
This is a mouse model study; protecting genetically engineered mice from memory deficits does not guarantee the same approach will be safe or effective in human Alzheimer's disease, which the subsequent two decades of human trials have shown is a much harder problem.
How this study scored 58/100
Published in a top-tier journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 10 / 10 | Tier 1 — top-tier general journal (Nature) |
| Journal's citation record | 4 / 4 | Nature: journal h-index 1,841 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2000 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 7 / 7 | Cited 1,504 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 53.7 citations a year over 28 year(s) since 2000 |
| Impact for its field and year | 6 / 6 | Cited 66.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 4 / 6 | Cited by 41 other studies in this library |
| Still being cited | 2 / 4 | Cited 30 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Gary W. Arendash: h-index 60 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of South Florida: institution h-index 806 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 11140686) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 58 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
41 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Caregiving from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.